Sarasota, Florida, U.S., October 13, 2026
Immorta Bio, Inc. has announced progress in its development of an artificial intelligence (AI)-designed senolytic immunotherapy targeting diseases associated with aging. The biotechnology company is combining computational drug design, immunotherapy research and senescence biology to investigate approaches that could selectively target harmful senescent cells. These cells stop dividing but can remain metabolically active, releasing inflammatory molecules that may contribute to tissue dysfunction and age-related disease. Although cellular senescence plays important roles in wound healing and tumor suppression, the accumulation of senescent cells has been associated with chronic inflammation and several degenerative conditions. Immorta Bio’s research aims to develop therapeutic strategies that remove or control these cells while limiting damage to healthy tissue. The program reflects growing interest in senolytic therapies, which seek to address biological mechanisms associated with aging rather than treating individual symptoms alone. However, the company’s AI-designed immunotherapy remains a developing research approach, and its clinical effectiveness, safety and potential applications will require rigorous experimental and clinical validation.
SenoMune-0257 Uses AI-Designed Peptide Technology
The investigational candidate, SenoMune™-0257, is a synthetic peptide comprising nine amino acids, developed using artificial intelligence-assisted discovery and laboratory testing. According to Immorta Bio, the peptide is designed to stimulate cytotoxic T cells, a type of immune cell capable of identifying and eliminating targeted cells. The company reports that preclinical laboratory studies demonstrated selective elimination of senescent cells under the conditions tested, while sparing healthy cells. This approach differs from conventional small-molecule senolytics, which seek to remove senescent cells through pharmacological mechanisms and may face challenges involving off-target toxicity. Immorta Bio aims to combine the targeted activity of immunotherapy with the potential manufacturing advantages of a synthetic peptide drug. The company also proposes that immune-mediated targeting could support longer-lasting immune recognition, although the durability and specificity of these effects must be established through additional research. These findings are preclinical and have not yet demonstrated safety or efficacy in humans.
Senescent Cells and Age-Related Disease Research
Cellular senescence is a biological process in which cells permanently or persistently stop dividing in response to stress, damage or other signals. Senescent cells can release inflammatory molecules and other substances collectively known as the senescence-associated secretory phenotype (SASP). While senescence can help suppress tumors and support wound healing, the accumulation of these cells in tissues has been associated with chronic inflammation, impaired tissue function and several age-related conditions. Researchers are investigating whether selectively removing harmful senescent cells could improve outcomes in conditions affecting the cardiovascular system, liver, kidneys, lungs and nervous system. Immorta Bio’s research builds on its SenoVax™ senolytic immunotherapy platform, which investigates immune-based approaches to targeting senescent cells, including cells associated with tumors. The company used insights from its earlier research to identify potential peptide candidates through computational screening and laboratory experiments. However, results obtained in laboratory systems or animal models cannot reliably predict clinical outcomes. The potential benefits of SenoMune-0257 across multiple age-related diseases remain unproven, and each proposed application will require appropriate scientific and clinical validation.
Advertisement
Immorta Bio Plans Clinical Development in 2026
Immorta Bio stated that it had completed its planned preclinical studies for SenoMune-0257 and was preparing to enter clinical development in 2026, with initial human evaluation anticipated before the end of the year. Progression into human studies will depend on applicable regulatory requirements and the availability of supporting safety and manufacturing data. Initial clinical evaluation would be expected to focus on establishing safety, tolerability, dosing and early biological activity before any conclusions about therapeutic effectiveness could be drawn. The company also intends to use its AI-assisted discovery process to identify additional peptide candidates targeting senescence-associated and other disease-related biological mechanisms. This strategy could potentially create a pipeline of candidates that are simpler to manufacture than individualized cellular therapies, although the claimed manufacturing and cost advantages will need to be demonstrated. SenoMune-0257 remains investigational, and its safety and effectiveness in humans have not been established. Future clinical findings will determine whether this AI-designed senolytic immunotherapy can advance toward meaningful treatment options for age-related diseases.
Source: Immorta Bio press release
